Natco Pharma announces executive changes due to retirement, resignation

Natco Pharma (BSE: 524816) has announced significant leadership transitions within the company, effective June 30, 2025. Dr. Muddasaani Pulla Reddy, Executive Vice President for Research and Development, and Mr. Ch. Srinivas, Senior Vice President of Demand and Supply, will be superannuating. Additionally, Mr. R. Sridhar Reddy, Senior Vice President – GCQA, has resigned from his position. The company has filed the required disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including details of the changes as per SEBI circulars. Natco Pharma confirmed that there are no inter-director relationships involved in these changes.